ACN Newswire Read More Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial indie 1 10 月 5 minutes MENLO PARK, CA and HELSINKI, F […]
ACN Newswire Read More Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors indie 10 2 月 4 minutes FOSTER CITY, Calif. and HANGZH […]
